We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Read MoreHide Full Article
Shares of Madrigal Pharmaceuticals (MDGL - Free Report) lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.
Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH). Subsequently, the drug became the first and only FDA-approved therapy that targets the underlying causes of NASH.
In the past three months, Madrigal shares have gained 27.1% against the industry’s 11.7% decline.
Image Source: Zacks Investment Research
MDGL’s Preliminary Q4 & FY24 Results
Madrigal reported preliminary fourth-quarter 2024 revenues from Rezdiffra sales in the $100-$103 million range.
For the full year, MDGL announced preliminary revenues in the $177-$180 million band from the drug’s sales since its launch in April 2024. Per the company, more than 11,800 patients are on Rezdiffra treatment as of year-end 2024.
Preliminary report suggests that Madrigal’s year-end 2024 cash, cash equivalents, restricted cash and marketable securities approximately amount to $931 million.
MDGL’s Pipeline Update
A regulatory filing, seeking approval for Rezdiffra for the same indication is currently under review in the EU. A final decision is expected in mid-2025. Subject to approval, Madrigal plans to initiate a country-by-country launch of the drug in the EU starting with Germany in the second half of 2025.
As the FDA approved Rezdiffra under the accelerated pathway, the continued approval will be based on promising long-term safety and efficacy data from the pivotal phase III MAESTRO-NASH biopsy study. This late-stage study, which provided the data for the drug's accelerated approval for NASH, is ongoing as an outcomes study. The goal is to generate confirmatory data that could verify the clinical benefits and support the full approval of Rezdiffra for the noncirrhotic NASH indication.
In addition to the MAESTRO-NASH study, a second phase III outcomes study is underway, evaluating the progression to liver decompensation events in patients with well-compensated NASH cirrhosis treated with Rezdiffra compared with placebo. This second outcomes study completed enrolling patients during the last reported quarter. Positive results from this study could make Rezdiffra the first approved treatment for patients with compensated cirrhosis, broadening its eligible patient group and potentially supporting full approval for noncirrhotic NASH.
These ongoing studies demonstrate Madrigal's commitment to establishing the drug as the standard-of-care treatment for NASH.
Madrigal Pharmaceuticals, Inc. Price and Consensus
In the past 30 days, Castle Biosciences’ earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 24.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 28.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have increased from $3.94 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 9.1%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Shares of Madrigal Pharmaceuticals (MDGL - Free Report) lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.
Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH). Subsequently, the drug became the first and only FDA-approved therapy that targets the underlying causes of NASH.
In the past three months, Madrigal shares have gained 27.1% against the industry’s 11.7% decline.
Image Source: Zacks Investment Research
MDGL’s Preliminary Q4 & FY24 Results
Madrigal reported preliminary fourth-quarter 2024 revenues from Rezdiffra sales in the $100-$103 million range.
For the full year, MDGL announced preliminary revenues in the $177-$180 million band from the drug’s sales since its launch in April 2024. Per the company, more than 11,800 patients are on Rezdiffra treatment as of year-end 2024.
Preliminary report suggests that Madrigal’s year-end 2024 cash, cash equivalents, restricted cash and marketable securities approximately amount to $931 million.
MDGL’s Pipeline Update
A regulatory filing, seeking approval for Rezdiffra for the same indication is currently under review in the EU. A final decision is expected in mid-2025. Subject to approval, Madrigal plans to initiate a country-by-country launch of the drug in the EU starting with Germany in the second half of 2025.
As the FDA approved Rezdiffra under the accelerated pathway, the continued approval will be based on promising long-term safety and efficacy data from the pivotal phase III MAESTRO-NASH biopsy study. This late-stage study, which provided the data for the drug's accelerated approval for NASH, is ongoing as an outcomes study. The goal is to generate confirmatory data that could verify the clinical benefits and support the full approval of Rezdiffra for the noncirrhotic NASH indication.
In addition to the MAESTRO-NASH study, a second phase III outcomes study is underway, evaluating the progression to liver decompensation events in patients with well-compensated NASH cirrhosis treated with Rezdiffra compared with placebo. This second outcomes study completed enrolling patients during the last reported quarter. Positive results from this study could make Rezdiffra the first approved treatment for patients with compensated cirrhosis, broadening its eligible patient group and potentially supporting full approval for noncirrhotic NASH.
These ongoing studies demonstrate Madrigal's commitment to establishing the drug as the standard-of-care treatment for NASH.
Madrigal Pharmaceuticals, Inc. Price and Consensus
Madrigal Pharmaceuticals, Inc. price-consensus-chart | Madrigal Pharmaceuticals, Inc. Quote
MDGL’s Zacks Rank & Stocks to Consider
Madrigal currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) , CytomX Therapeutics (CTMX - Free Report) and BioMarin Pharmaceutical (BMRN - Free Report) , each sportinga Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, Castle Biosciences’ earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 24.6%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 28.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have increased from $3.94 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 9.1%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%.